We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
100.00 | 0.89% | 11,368.00 | 11,370.00 | 11,372.00 | 11,390.00 | 11,288.00 | 11,288.00 | 105,340 | 08:33:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.62 | 176.38B |
Date | Subject | Author | Discuss |
---|---|---|---|
12/4/2022 17:58 | Had a superb run, just a bit of profit taking. | montyhedge | |
12/4/2022 12:44 | ASTRAZENECA : Buy rating from Berenberg 04/12/2022 | 12:40pm BST In a research note published by Luisa Hector, Berenberg advises its customers to buy the stock. The target price is revised upwards from GBX 10000 to GBX 12000. | waldron | |
08/4/2022 19:40 | have not followed this stock for a while - what a mistake . now chart shows a NOR situation and how long is s piece of string ! | arja | |
08/4/2022 16:27 | Long term, holder, yes institutions must be piling in with new cash. | chc15 | |
08/4/2022 16:03 | Institutions I assume. I bought a fair amount, in my terms before the rise and am happily holding. | our haven | |
08/4/2022 15:45 | I'm buying it... | mapocho | |
08/4/2022 14:43 | Amazed there is so little chatter on this board. Up 25% in a month. Keeping entire FTSE up whilst Europe and US markets fall.But no interest here? Who is buying this? | paa65 | |
07/4/2022 07:37 | James Gordon from JP Morgan retains his positive opinion on the stock with a Buy rating. The target price is reviewed upwards from GBX 10000 to GBX 12000. | la forge | |
06/4/2022 17:00 | Analysts at Deutsche Bank hiked their target price for AstraZeneca shares from 10,500.0p to 11,500.0p, telling clients it saw no reason to tilt towards so-called 'value' names in the space and away from 'growth'. Deutsche Bank conceded that an environment of rising interest rates would normally hardly be seen as auguring positively for a defensive sector to outperform. However, DB highlighted that these weren't exactly normal times. "This being a geopolitically-chall Within the sector, more highly-valued growth names such as AstraZeneca and Novo Nordisk had been the standout outperformers, versus the likes of GlaxoSmithKline, Novartis or Sanofi. | misca2 | |
06/4/2022 10:09 | Deutsche Bank raises AstraZeneca price target to 11,500 (10,500) pence - 'buy' | philanderer | |
05/4/2022 16:24 | As mentioned, big momentum here, institutions buying at this level, so why sell. | chc15 | |
05/4/2022 15:59 | WD Waldron, good forecast! | dudishes | |
05/4/2022 07:15 | Todays the day it might well break thru an important Resistence level | waldron | |
05/4/2022 07:14 | (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Monday its AZD8233 drug at 50-milligram dose lowered the levels of low-density lipoprotein cholesterol by 73% among people with high-risk hypercholesterolemia The dose-ranging clinical trial, dubbed Etesia, evaluated AZD8233 at 15 mg, 50 mg and 90 mg doses administered monthly via subcutaneous injection within a 12-week period. Results showed that the drug also cut the PCSK9 enzyme levels by 89%, with sustained reductions observed over the dosing intervals. A decrease in PCSK9 raises LDL receptor levels, which in turn lowers cholesterol levels in the bloodstream, reducing the risk of developing heart disease. The safety, efficacy and tolerability of AZD8233 in hypercholesterolemia are being examined in the Solano phase 2b trial, with results expected later in the year. AstraZeneca gained nearly 1% on Monday's close. Price (GBP): £10142.00, Change: £+66.00, Percent Change: +0.66% | waldron | |
31/3/2022 18:44 | Mind u, mkts going down after putins demands, so taking profits not a bad thing. | chc15 | |
31/3/2022 18:15 | No harm in taking profits, but feel there is good momentum here. | chc15 | |
31/3/2022 15:48 | I'm out at £102. This is above quite a few broker PT's so happy to take profits. Currently way above 20 mda, too high too quickly, will buy back when it settles. Good Luck all. | beckers2008 | |
31/3/2022 12:22 | We surging here, can only mean there is strong institutional buying at this level, wow. | chc15 | |
29/3/2022 14:09 | Azn holders now in the 100 club..olaay olay olay. | hotfinance14 | |
29/3/2022 12:31 | May 2020 I said it would exceed 100 , bit premature that was , however where is our serial doomster Buywell ? Buybadly . | holts | |
29/3/2022 09:48 | Onwards and Upwards. Let's see it can close above £100 later today. | gateside | |
29/3/2022 09:37 | Sp through the £100 level for the first time - a bit of a landmark price! | ygor705 | |
27/3/2022 19:39 | Ianood - A split is what a meant - I got it the wrong way round! | gateside |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions